- Report
- April 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- March 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- January 2026
- 185 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- March 2025
- 182 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 383 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 396 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 566 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 187 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 273 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 471 Pages
Global
From €5124EUR$5,850USD£4,447GBP

The Respiratory Disease market within the context of Pulmonary Medicine is a broad field of study that focuses on the diagnosis, treatment, and prevention of diseases that affect the lungs and airways. This includes conditions such as asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary hypertension. Treatment options for these conditions range from lifestyle modifications to medications, and in some cases, surgery. Research in this field is ongoing, with the aim of improving the quality of life for those affected by respiratory diseases.
Companies in the Respiratory Disease market include AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, and Pfizer. These companies are involved in the development of new treatments and therapies for respiratory diseases, as well as the manufacture and distribution of existing treatments. Show Less Read more